RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Agile Therapeutics Stock

Agile Therapeutics Revenue 2024

Agile Therapeutics Revenue

37.58 M USD

Ticker

AGRX

ISIN

US00847L1008

WKN

A1135H

In 2024, Agile Therapeutics's sales reached 37.58 M USD, a 91.78% difference from the 19.59 M USD sales recorded in the previous year.

The Agile Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e143.767,38
2028e163.726,48
2027e112.19,47
2026e67.6115,70
2025e51.9520,43
2024e37.5828,25
202319.5954,18
202210.8837,22
20214.1-161,46
20200.7562,67
2019--
2018--
2017--
2016--
2015--
2014--
2013--
2012--

Agile Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Agile Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Agile Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Agile Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Agile Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Agile Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Agile Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Agile Therapeutics’s growth potential.

Agile Therapeutics Revenue, EBIT and net profit per share

DateAgile Therapeutics RevenueAgile Therapeutics EBITAgile Therapeutics Net Income
2029e143.76 M undefined0 undefined0 undefined
2028e163.72 M undefined99.72 M undefined25.91 M undefined
2027e112.1 M undefined53.3 M undefined6.48 M undefined
2026e67.61 M undefined24.38 M undefined5.04 M undefined
2025e51.95 M undefined13.53 M undefined2.82 M undefined
2024e37.58 M undefined5.43 M undefined2 M undefined
202319.59 M undefined-19.88 M undefined-14.47 M undefined
202210.88 M undefined-41.44 M undefined-25.41 M undefined
20214.1 M undefined-71.01 M undefined-71.07 M undefined
2020750,000 undefined-49.05 M undefined-51.85 M undefined
20190 undefined-18.86 M undefined-18.61 M undefined
20180 undefined-18.52 M undefined-19.78 M undefined
20170 undefined-26.81 M undefined-28.3 M undefined
20160 undefined-29.72 M undefined-28.74 M undefined
20150 undefined-33.09 M undefined-30.34 M undefined
20140 undefined-18.52 M undefined-16.08 M undefined
20130 undefined-12.73 M undefined-14.32 M undefined
20120 undefined-23.32 M undefined-23.86 M undefined

Agile Therapeutics stock margins

The Agile Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Agile Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Agile Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Agile Therapeutics's sales revenue. A higher gross margin percentage indicates that the Agile Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Agile Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Agile Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Agile Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Agile Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Agile Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Agile Therapeutics Margin History

Agile Therapeutics Gross marginAgile Therapeutics Profit marginAgile Therapeutics EBIT marginAgile Therapeutics Profit margin
2029e54.18 %0 %0 %
2028e54.18 %60.91 %15.83 %
2027e54.18 %47.54 %5.78 %
2026e54.18 %36.06 %7.46 %
2025e54.18 %26.03 %5.42 %
2024e54.18 %14.45 %5.31 %
202354.18 %-101.49 %-73.83 %
202237.22 %-380.88 %-233.55 %
2021-161.46 %-1,731.95 %-1,733.41 %
202062.67 %-6,540 %-6,913.33 %
201954.18 %0 %0 %
201854.18 %0 %0 %
201754.18 %0 %0 %
201654.18 %0 %0 %
201554.18 %0 %0 %
201454.18 %0 %0 %
201354.18 %0 %0 %
201254.18 %0 %0 %

Agile Therapeutics Aktienanalyse

What does Agile Therapeutics do?

Agile Therapeutics Inc is a biopharmaceutical company specializing in the development of women's products. The company was founded in 1997 and is based in Princeton, New Jersey, USA. Agile Therapeutics Inc focuses on manufacturing a unique range of women's products called the Women's Healthcare Division. These products aim to help women maintain their health and well-being by addressing their health issues and improving their quality of life. The products of Agile Therapeutics target various areas, including birth control, menstrual discomfort, and frequent infections. The company offers a variety of products to meet a wide range of needs. An important area in which Agile Therapeutics is active is birth control. The company has developed an innovative transdermal contraception system called Twirla, which is currently approved in the USA. In this system, the hormone Gestodene is absorbed through the skin, preventing pregnancy. The Twirla product is easy to use, safe, and effective. It may also offer several other benefits, such as higher tolerability compared to other contraceptive methods. Agile Therapeutics has also developed other products aimed at improving women's quality of life. This includes the product AG200-15, marketed as a treatment for severe menstrual discomfort. It is a progesterone-based transdermal system that allows for continuous dosing over several weeks, thereby reducing menstrual discomfort. Another product is AG890, marketed as a treatment for frequent vaginal infections such as yeast infections. This system aims to help women prevent or treat these infections and also aids in the prevention of recurring infections. The business model of Agile Therapeutics is based on the development and commercialization of women's products that address a significant need in society. The company enters into strategic partnerships with other companies and institutions to effectively and efficiently market its products. Agile Therapeutics also has a strong presence in research and development. Through intensive research efforts, the company has produced a range of innovative products that are in various stages of testing and trial. Agile Therapeutics works closely with the FDA (Food and Drug Administration) to ensure that its products meet all regulatory requirements. Overall, Agile Therapeutics is an innovative company specializing in the development of women's products. With its focus on the health needs of women, the company aims to improve the quality of life for women worldwide. With a wide range of products and a strong business model, Agile Therapeutics is well-positioned for a promising future. Agile Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Agile Therapeutics's Sales Figures

The sales figures of Agile Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Agile Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Agile Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Agile Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Agile Therapeutics stock

How much revenue did Agile Therapeutics generate this year?

Agile Therapeutics has achieved a revenue of 37.58 M USD this year.

How much was the turnover of the company Agile Therapeutics compared to the previous year?

The revenue of Agile Therapeutics has increased by 91.78% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Agile Therapeutics?

The revenue of Agile Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Agile Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Agile Therapeutics so important for investors?

The revenue of Agile Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Agile Therapeutics pay?

Over the past 12 months, Agile Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agile Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Agile Therapeutics?

The current dividend yield of Agile Therapeutics is .

When does Agile Therapeutics pay dividends?

Agile Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Agile Therapeutics?

Agile Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Agile Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Agile Therapeutics located?

Agile Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Agile Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Agile Therapeutics from 12/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/24/2024.

When did Agile Therapeutics pay the last dividend?

The last dividend was paid out on 12/24/2024.

What was the dividend of Agile Therapeutics in the year 2023?

In the year 2023, Agile Therapeutics distributed 0 USD as dividends.

In which currency does Agile Therapeutics pay out the dividend?

The dividends of Agile Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Agile Therapeutics

Our stock analysis for Agile Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agile Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.